New & Notable

FDA approves Merilog, first NovoLog biosimilar for diabetes

FDA approves Merilog, first NovoLog biosimilar for diabetes

The FDA approved Merilog (insulin-aspart-szjj), the first biosimilar to NovoLog, enhancing insulin accessibility and competition while potentially lowering costs.

How PBMs limit access to MS therapies

How PBMs limit access to MS therapies

Pharmacy benefit managers inflate specialty generic prices, restrict pharmacy choice and increase patient costs, leaving many life-saving multiple sclerosis therapies inaccessible.

Emerging vision risks linked to semaglutide, tirzepatide

Emerging vision risks linked to semaglutide, tirzepatide

Recent data points to potential ophthalmic complications, including optic neuropathy and maculopathy, in patients treated with semaglutide and tirzepatide.

Understanding tirzepatide compounding restrictions

Understanding tirzepatide compounding restrictions

The FDA’s tirzepatide compounding rules present challenges for pharmacies, with deadlines in February and March of 2025, requiring compliance to avoid legal and regulatory risks.

View All The Latest News

Insights

Insights is research conducted by and for TechTarget Xtelligent Healthcare. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.

Access All Reports

Healthcare Strategies: A Podcast

  • A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.

    Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.

    View All Episodes

Latest News

View All The Latest News

Features

View All Features